Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Pfizer earnings preview: Leerink trims estimates
November 3, 2025 4:00 PM ESTPfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ahead of the release.
Leerink reduced its third-quarter earnings-per-share estimate by $0.10, or 13%, to $0.70, and full-year 2025 EPS by 3% to $3.04, within company guidance ($2.90$3.10).
The firm said it cut its 2025 Paxlovid... More



